Journal of pediatric hematology/oncology
-
J. Pediatr. Hematol. Oncol. · May 2013
Bereaved parents and siblings offer advice to health care providers and researchers.
To determine how to improve care for families by obtaining their advice to health care providers and researchers after a child's death from cancer. ⋯ Many participants were pleased with the care the child with cancer received, but others noted areas in need of improvement, particularly medical communication and continuity of care. Additional research is needed to inform interventions to improve services for families of children with life-limiting conditions.
-
J. Pediatr. Hematol. Oncol. · May 2013
Case ReportsSuccessful treatment of refractory immune thrombocytopenia with rituximab in a 10-week-old infant.
Immune thrombocytopenic purpura (ITP) that is unresponsive to conventional treatment is uncommon. In this situation, additional therapeutic options are limited and management is challenging. We describe the case of a 10-week-old infant that developed life-threatening ITP that was unresponsive to immunoglobulin and corticosteroids that was successfully managed with the monoclonal antibody rituximab. The literature on the use of rituximab in nonresponsive ITP is reviewed.
-
J. Pediatr. Hematol. Oncol. · Apr 2013
ReviewSystematic review of transition from adolescent to adult care in patients with sickle cell disease.
Awareness and practice of appropriate treatment for childhood sickle cell disease (SCD) has improved, and survival rates have increased significantly. Today, most patients will eventually require treatment in the adult-care setting. Adolescents who are transferred out from successful pediatric programs face numerous challenges regarding continuity of care, and mortality rates remain high in this age group. ⋯ A secondary search of 5 additional sources was conducted regarding relevant guidelines or meta-analyses. Current publications describe barriers to continuity of care in this group, proposals for improving the transition process, and contemporary models for SCD care transition. Clinical recommendations include development of a flexible, patient-centric transition plan and education for health care providers.
-
J. Pediatr. Hematol. Oncol. · Apr 2013
Predicting response to rFVIIa in neonates with intractable bleeding or severe coagulation disturbances.
To date, clinical experience with recombinant factor VIIa (rFVIIa) in neonates is rather limited because of the lack of controlled studies. ΑIM: The objective of this study was to present further experience from our center with regard to the use of rFVIIa in newborns with severe bleeding or coagulopathy resistant to conventional therapy and to determine factors affecting the clinical outcome. ⋯ In this neonatal group with intractable bleeding and/or severe coagulation disturbances, rFVIIa was more effective in early intervention as rescue therapy, without any adverse events in all neonates. Upon failure to achieve hemostasis with initial administration of blood products, fast intervention with rFVIIa could be considered in neonates with serious bleeding and coagulation disorders.
-
J. Pediatr. Hematol. Oncol. · Mar 2013
Randomized Controlled Trial Comparative StudySedation for short hemato-oncologic invasive procedures in children: comparison of propofol-remifentanil and propofol-fentanyl.
Short hemato-oncologic procedures are often painful in children, and sedation should be performed outside the operating room. ⋯ During short hemato-oncologic interventions in children, the PR combination is a suitable one for early recovery.